LENZ Therapeutics (NASDAQ:LENZ) Price Target Raised to $47.00

LENZ Therapeutics (NASDAQ:LENZ) had its target price hoisted by equities research analysts at Citigroup from $44.00 to $47.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s target price suggests a potential upside of 80.55% from the company’s current price.

Separately, TD Cowen initiated coverage on LENZ Therapeutics in a research note on Tuesday. They set a “buy” rating and a $60.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $41.67.

LENZ Therapeutics Stock Up 2.0 %

Shares of LENZ traded up $0.51 during trading hours on Thursday, reaching $26.03. 200,635 shares of the company traded hands, compared to its average volume of 163,941. The stock has a fifty day simple moving average of $24.09 and a 200 day simple moving average of $27.02. LENZ Therapeutics has a fifty-two week low of $14.42 and a fifty-two week high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04). As a group, equities research analysts anticipate that LENZ Therapeutics will post -2.18 EPS for the current fiscal year.

Institutional Trading of LENZ Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of LENZ. Mirae Asset Global Investments Co. Ltd. acquired a new position in LENZ Therapeutics during the fourth quarter valued at approximately $29,000. KLP Kapitalforvaltning AS purchased a new position in shares of LENZ Therapeutics in the 4th quarter valued at $46,000. Tower Research Capital LLC TRC lifted its holdings in shares of LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock valued at $54,000 after acquiring an additional 1,151 shares in the last quarter. Virtus ETF Advisers LLC purchased a new stake in LENZ Therapeutics during the 4th quarter worth $67,000. Finally, SG Americas Securities LLC increased its holdings in LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after purchasing an additional 935 shares in the last quarter. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.